Retinal Angiomatous Proliferation and Intravitreal Bevacizumab Injection
Korean Journal of Ophthalmology
; : 213-215, 2007.
Article
de En
| WPRIM
| ID: wpr-13517
Bibliothèque responsable:
WPRO
ABSTRACT
PURPOSE: To evaluate the short-term efficacy and safety of intravitreal bevacizumab injection (IVBI) in patients with retinal angiomatous proliferation (RAP). METHODS: Seven eyes of 5 patients with RAP were included in this study. All of the eyes evidenced stage 2 RAP lesions, except for one eye with a stage 3 lesion. IVBI (1.25 mg/0.05 cc) were conducted at 4 or 6-week intervals. Complete ocular examinations, angiographic results and optical coherence tomographic findings before and after the IVBI were analyzed at baseline and upon the follow-up visits. RESULTS: Seven eyes were studied in 5 patients who had undergone IVBI. Partial (3 eyes) or complete (4 eyes) regression of RAP was noted after IVBI in all of the studied eyes. Visual acuity improved in 5 of the eyes, and was stable in 2 of the eyes. One eye evidenced severe intraocular inflammation after IVBI and a subsequent development of new RAP, which was controlled with vitrectomy and repeat IVBI. CONCLUSIONS: This treatment was effective over 6 months, stabilizing or improving visual acuity and reducing angiographic leakage. These short-term results suggest that IVBI may constitute a promising therapeutic option, particularly in the early stages of RAP.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Corps vitré
/
Angiographie fluorescéinique
/
Acuité visuelle
/
Néovascularisation rétinienne
/
Études de suivi
/
Résultat thérapeutique
/
Vitréorétinopathie proliférante
/
Inhibiteurs de l'angiogenèse
/
Facteur de croissance endothéliale vasculaire de type A
/
Fond de l'oeil
Type d'étude:
Observational_studies
/
Prognostic_studies
Limites du sujet:
Aged
/
Aged80
/
Female
/
Humans
/
Male
langue:
En
Texte intégral:
Korean Journal of Ophthalmology
Année:
2007
Type:
Article